Generic diabetes combo pill put to the test in healthy volunteers
NCT ID NCT07633054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested whether a new tablet containing empagliflozin and metformin works the same in the body as the reference drug Synjardy. Forty-two healthy adults took a single dose of each version under fed conditions. The goal was to check bioequivalence, meaning the two drugs release the same amount of active ingredient at the same rate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin/Metformin
- What this could lead to
- If the test tablet is shown to be equivalent, it could offer a more affordable or accessible option for managing type 2 diabetes.
- What could go wrong
- This was a small, early-stage study in healthy people, not patients. Results may not predict real-world effectiveness or safety in those with diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Axis Clinicals Latina, S.A. de C.V.
Mexico City, Mexico City, 07870, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a new drug form work the same? study tests two versions of SKI-O-703
- Diabetes drug copycat put to the test in healthy volunteers
- Diabetes drug showdown: are two pills equally effective?
- Generic diabetes combo drug put to the test in healthy volunteers
- Generic Alzheimer's patch put to the test in healthy volunteers
- New combo pill for heart failure put to the test in healthy volunteers